• OPEN AN ACCOUNT
Indian Indices
Nifty
22,502.00 35.90
(0.16%)
Sensex
74,005.94 88.91
( 0.12%)
Bank Nifty
48,199.50 83.85
( 0.17%)
Nifty IT
33,438.75 56.90
( 0.17%)
Global Indices
Nasdaq
16,685.97 -12.35
(-0.07%)
Dow Jones
40,003.59 134.21
(0.34%)
Hang Seng
19,553.61 177.08
(0.91%)
Nikkei 225
38,787.38 -132.88
(-0.34%)
Forex
USD-INR
83.47 0.01
(0.01%)
EUR-INR
90.76 0.22
(0.25%)
GBP-INR
105.79 0.36
(0.34%)
JPY-INR
0.54 0.00
(0.51%)

EQUITY - MARKET SCREENER

Dr Reddys Laboratories Ltd
Industry :  Pharmaceuticals - Indian - Bulk Drugs & Formln
BSE Code
ISIN Demat
Book Value()
500124
INE089A01023
1453.1267897
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
DRREDDY
22.34
97001.49
EPS(TTM)
Face Value()
Div & Yield %
260.28
5
0.69
 

Dr Reddys Laboratories Ltd
Dr Reddy's Labs launches generic Oracea capsules in US markets
May 06,2024

Oracea is a tetracycline antibiotic. It is used to treat blemishes, bumps, and acne-like lesions caused by rosacea in adults. It works by reducing skin inflammation caused by rosacea.

Doxycycline capsules had estimated annual sales of USD 128 million in the US (IQVIA MAT February 2024).

Dr Reddy's Laboratories is engaged in providing medicines. The firm operates in three segments: global generics, pharmaceutical services and active ingredients (PSAI) and proprietary products.

The drug major's consolidated net profit increased 10.57% to Rs 1,378.9 crore on 6.57% rise in revenues to Rs 7,214.8 crore in Q3 FY24 over Q3 FY23.

The scrip fell 0.42% to currently trade at Rs 6323.15 on the BSE.